Glioblastoma Multiforme Treatment Market - Global Outlook and Forecast 2022-2028

March 2022 | 68 pages | ID: G072ACCA0AFCEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Glioblastoma Multiforme Treatment in Global, including the following market information:

Global Glioblastoma Multiforme Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Glioblastoma Multiforme Treatment market was valued at 564.1 million in 2021 and is projected to reach US$ 990.5 million by 2028, at a CAGR of 8.4% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Bevacizumab (Avastin) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Glioblastoma Multiforme Treatment include AbbVie, Inc, Activartis GmbH, Agenus Inc, Arog Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, Cortice Biosciences and Exelixis Inc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glioblastoma Multiforme Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Glioblastoma Multiforme Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, by Type, 2021 (%)

• Bevacizumab (Avastin)
• Carmustine (BiCNU)
• Temozolomide (Temodar and Temodal and Temcad)

Global Glioblastoma Multiforme Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Glioblastoma Multiforme Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Glioblastoma Multiforme Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Glioblastoma Multiforme Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Glioblastoma Multiforme Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie, Inc
• Activartis GmbH
• Agenus Inc
• Arog Pharmaceuticals, Inc
• Bristol-Myers Squibb Company
• Cavion LLC
• Celldex Therapeutics Inc
• Cortice Biosciences
• Exelixis Inc
• F. Hoffmann-La Roche Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Glioblastoma Multiforme Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Glioblastoma Multiforme Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT OVERALL MARKET SIZE

2.1 Global Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028
2.2 Global Glioblastoma Multiforme Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Glioblastoma Multiforme Treatment Players in Global Market
3.2 Top Global Glioblastoma Multiforme Treatment Companies Ranked by Revenue
3.3 Global Glioblastoma Multiforme Treatment Revenue by Companies
3.4 Top 3 and Top 5 Glioblastoma Multiforme Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Glioblastoma Multiforme Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Glioblastoma Multiforme Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Glioblastoma Multiforme Treatment Market Size Markets, 2021 & 2028
  4.1.2 Bevacizumab (Avastin)
  4.1.3 Carmustine (BiCNU)
  4.1.4 Temozolomide (Temodar and Temodal and Temcad)
4.2 By Type - Global Glioblastoma Multiforme Treatment Revenue & Forecasts
  4.2.1 By Type - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Glioblastoma Multiforme Treatment Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Glioblastoma Multiforme Treatment Revenue & Forecasts
  5.2.1 By Application - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Glioblastoma Multiforme Treatment Market Size, 2021 & 2028
6.2 By Region - Global Glioblastoma Multiforme Treatment Revenue & Forecasts
  6.2.1 By Region - Global Glioblastoma Multiforme Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Glioblastoma Multiforme Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Glioblastoma Multiforme Treatment Revenue, 2017-2028
  6.3.2 US Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.3.3 Canada Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.3.4 Mexico Glioblastoma Multiforme Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Glioblastoma Multiforme Treatment Revenue, 2017-2028
  6.4.2 Germany Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.3 France Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.4 U.K. Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.5 Italy Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.6 Russia Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.4.8 Benelux Glioblastoma Multiforme Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Glioblastoma Multiforme Treatment Revenue, 2017-2028
  6.5.2 China Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.5.3 Japan Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.5.4 South Korea Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.5.6 India Glioblastoma Multiforme Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Glioblastoma Multiforme Treatment Revenue, 2017-2028
  6.6.2 Brazil Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.6.3 Argentina Glioblastoma Multiforme Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, 2017-2028
  6.7.2 Turkey Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.7.3 Israel Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Glioblastoma Multiforme Treatment Market Size, 2017-2028
  6.7.5 UAE Glioblastoma Multiforme Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie, Inc
  7.1.1 AbbVie, Inc Corporate Summary
  7.1.2 AbbVie, Inc Business Overview
  7.1.3 AbbVie, Inc Glioblastoma Multiforme Treatment Major Product Offerings
  7.1.4 AbbVie, Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.1.5 AbbVie, Inc Key News
7.2 Activartis GmbH
  7.2.1 Activartis GmbH Corporate Summary
  7.2.2 Activartis GmbH Business Overview
  7.2.3 Activartis GmbH Glioblastoma Multiforme Treatment Major Product Offerings
  7.2.4 Activartis GmbH Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.2.5 Activartis GmbH Key News
7.3 Agenus Inc
  7.3.1 Agenus Inc Corporate Summary
  7.3.2 Agenus Inc Business Overview
  7.3.3 Agenus Inc Glioblastoma Multiforme Treatment Major Product Offerings
  7.3.4 Agenus Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.3.5 Agenus Inc Key News
7.4 Arog Pharmaceuticals, Inc
  7.4.1 Arog Pharmaceuticals, Inc Corporate Summary
  7.4.2 Arog Pharmaceuticals, Inc Business Overview
  7.4.3 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Major Product Offerings
  7.4.4 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.4.5 Arog Pharmaceuticals, Inc Key News
7.5 Bristol-Myers Squibb Company
  7.5.1 Bristol-Myers Squibb Company Corporate Summary
  7.5.2 Bristol-Myers Squibb Company Business Overview
  7.5.3 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Major Product Offerings
  7.5.4 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.5.5 Bristol-Myers Squibb Company Key News
7.6 Cavion LLC
  7.6.1 Cavion LLC Corporate Summary
  7.6.2 Cavion LLC Business Overview
  7.6.3 Cavion LLC Glioblastoma Multiforme Treatment Major Product Offerings
  7.6.4 Cavion LLC Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.6.5 Cavion LLC Key News
7.7 Celldex Therapeutics Inc
  7.7.1 Celldex Therapeutics Inc Corporate Summary
  7.7.2 Celldex Therapeutics Inc Business Overview
  7.7.3 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Major Product Offerings
  7.7.4 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.7.5 Celldex Therapeutics Inc Key News
7.8 Cortice Biosciences
  7.8.1 Cortice Biosciences Corporate Summary
  7.8.2 Cortice Biosciences Business Overview
  7.8.3 Cortice Biosciences Glioblastoma Multiforme Treatment Major Product Offerings
  7.8.4 Cortice Biosciences Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.8.5 Cortice Biosciences Key News
7.9 Exelixis Inc
  7.9.1 Exelixis Inc Corporate Summary
  7.9.2 Exelixis Inc Business Overview
  7.9.3 Exelixis Inc Glioblastoma Multiforme Treatment Major Product Offerings
  7.9.4 Exelixis Inc Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.9.5 Exelixis Inc Key News
7.10 F. Hoffmann-La Roche Ltd.
  7.10.1 F. Hoffmann-La Roche Ltd. Corporate Summary
  7.10.2 F. Hoffmann-La Roche Ltd. Business Overview
  7.10.3 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Major Product Offerings
  7.10.4 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue in Global Market (2017-2022)
  7.10.5 F. Hoffmann-La Roche Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Glioblastoma Multiforme Treatment Market Opportunities & Trends in Global Market
Table 2. Glioblastoma Multiforme Treatment Market Drivers in Global Market
Table 3. Glioblastoma Multiforme Treatment Market Restraints in Global Market
Table 4. Key Players of Glioblastoma Multiforme Treatment in Global Market
Table 5. Top Glioblastoma Multiforme Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Glioblastoma Multiforme Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Glioblastoma Multiforme Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Glioblastoma Multiforme Treatment Product Type
Table 9. List of Global Tier 1 Glioblastoma Multiforme Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Glioblastoma Multiforme Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Glioblastoma Multiforme Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Glioblastoma Multiforme Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Glioblastoma Multiforme Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Glioblastoma Multiforme Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Glioblastoma Multiforme Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Glioblastoma Multiforme Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie, Inc Corporate Summary
Table 31. AbbVie, Inc Glioblastoma Multiforme Treatment Product Offerings
Table 32. AbbVie, Inc Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Activartis GmbH Corporate Summary
Table 34. Activartis GmbH Glioblastoma Multiforme Treatment Product Offerings
Table 35. Activartis GmbH Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Agenus Inc Corporate Summary
Table 37. Agenus Inc Glioblastoma Multiforme Treatment Product Offerings
Table 38. Agenus Inc Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Arog Pharmaceuticals, Inc Corporate Summary
Table 40. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Product Offerings
Table 41. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Bristol-Myers Squibb Company Corporate Summary
Table 43. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Product Offerings
Table 44. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Cavion LLC Corporate Summary
Table 46. Cavion LLC Glioblastoma Multiforme Treatment Product Offerings
Table 47. Cavion LLC Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Celldex Therapeutics Inc Corporate Summary
Table 49. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Product Offerings
Table 50. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Cortice Biosciences Corporate Summary
Table 52. Cortice Biosciences Glioblastoma Multiforme Treatment Product Offerings
Table 53. Cortice Biosciences Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Exelixis Inc Corporate Summary
Table 55. Exelixis Inc Glioblastoma Multiforme Treatment Product Offerings
Table 56. Exelixis Inc Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)
Table 57. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 58. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Product Offerings
Table 59. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Glioblastoma Multiforme Treatment Segment by Type in 2021
Figure 2. Glioblastoma Multiforme Treatment Segment by Application in 2021
Figure 3. Global Glioblastoma Multiforme Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Glioblastoma Multiforme Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Glioblastoma Multiforme Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Glioblastoma Multiforme Treatment Revenue in 2021
Figure 8. By Type - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 12. US Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 24. China Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Glioblastoma Multiforme Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Glioblastoma Multiforme Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie, Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Activartis GmbH Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Agenus Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Cavion LLC Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cortice Biosciences Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Exelixis Inc Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)